The human malaria parasite has evolved Background:
Introduction
The malaria parasite Plasmodium falciparum causes the greatest disease burden and death in developing countries. In 2015, the World Health Organization reported 200 million clinical malaria cases with 400,000 cases resulting in death (WHO, 2016) . Majority of this burden is in sub-Saharan Africa, primarily in children under 5 years of age. With the newly introduced vaccine showing less than 50% reduction in clinical cases and its efficacy waning with time (Olotu et al., 2013) , the use of drugs for prophylaxis and treatment of malaria remains a key alternative in malaria control. To date, strategies for treatment of uncomplicated malaria is the use of artemisinin based combination therapies (ACTs), comprising of short acting artemisinin derivative and a long acting partner drug, a strategy intended to reduce the emergence of resistance (WHO, 2015) . However, the genetically flexible malaria parasite has evolved drug evasion mechanisms to all available antimalarial drugs, including the artemisinins (Miotto et al., 2015) .
Currently the ACTs are used widely in all malaria endemic countries; however, this is against the backdrop of high malaria transmissions, exposing the long acting partner drugs to strong selection pressures (White, 2002) . For instance, combination of amodiaquine and artesunate (AQ-ASN) is among the five recommended ACTs for treatment of uncomplicated malaria (WHO, 2016) . This combination is available as a fixed combination Coarsucam™/Winthop®, Sanofi-Aventis (Gil, 2008) . The ASN is a short acting drug with a half -life of <2hours (Robert et al., 2001; Tilley et al., 2016) . On the other hand, AQ is a prodrug that is rapidly metabolized to its active long acting metabolite desethylamodiaquine (DEAQ), with a half-life of more than 5 days (Churchill et al., 1985) . In a number of African countries, AQ-ASN is the first or a second line drug for treatment of uncomplicated malaria (Rwagacondo et al., 2004; Sondo et al., 2016; WHO, 2016) . In addition, AQ and sulfadoxine/pyrimethamine (AQ-SP) is used as a prophylactic combination, in children below 5 years of age in areas of highly seasonal transmission, such as sub-Sahel region (WHO, 2015) . Thus, AQ remains a useful drug in the treatment and prophylaxis of malaria.
AQ like chloroquine (CQ) belongs to 4-amino-quinolines class of antimalarial drugs and their mechanisms of resistance are predicted to be similar; however, AQ is active against some CQ resistant parasite strains ( (Bennett et al., 2007) . Thus, using the selected stable AQ resistant parasite line, we investigated the impact of SNP and/or transcript levels of P. berghei ortholog genes of the aforementioned markers on AQ resistance. Finally, the role of Kelch13 propeller, a protein domain involved in detecting intracellular oxidative stress resulting from artemisinin and other endoperoxides action and a marker for artemisinin resistance in P. falciparum (Leroy, 2017; Miotto et al., 2015; Straimer et al., 2015) was also studied.
Materials and methods
Parasites, host and compounds Male Swiss albino mice (6-7 weeks old) weighing 20±2g outbred at KEMRI Animal House (Nairobi, Kenya) were used to induce AQ resistance from sensitive parasite line of P. berghei ANKA (MRA-868, MR4, ATCC® Manassas, Virginia, 676m1cl1). The animals were kept in the animal house in standard polypropylene cages and fed on commercial rodent feed and water ad libitum. AQ, CQ, primaquine (PMQ), LM, artemether (ATM) and PQ were prepared freshly by dissolving in a solvent containing 3% ethanol and 7% Tween-80. In all the experiments involving use of laboratory mice, at least 3 mice were used per experimental group to allow the calculation of averages, standard deviation and statistical analysis.
Determination of 50% and 90% effective doses The 50% (ED 50 ) 90% (ED 90 ) and 99% (ED 99 ) effective doses, the doses that reduce parasitaemia by 50%, 90% and 99% respectively, after four consecutive drug dosages were determined following quantitative standard 4-Day Suppressive Test (4DT; Fidock et al., 2004) . Briefly, twenty-five mice were randomly infected intraperitoneally each with 1×10 6 parasites and then randomly allocated to the four test groups and the control group (five mice per group). Oral treatment with drug was initiated on day 0, (2-4 hrs postinfection) and continued for four days, days 0-3 (24, 48 and 72 hrs post-infection). Parasite density for ED 50 and ED 90 calculation was estimated microscopically (×100) on day 4 (96 hrs) post parasite inoculation using thin blood films made from tail blood snips. Parasite growth was also monitored on D2, D3, D4, D7, D9, D11 and D15 days post infection. Percentage chemo-suppression of each dose was calculated following the formula (Fidock et al., 2004): A-B/A×100. Where A = the mean parasitaemia in the negative control group and B the parasitaemia in the test group. The ED 50 and ED 90 were then estimated using linear regression line.
Submission of parasite to AQ pressure and Resistance Level Test AQ sensitive parasite was submitted to continuous AQ pressure. Six mice (three for the control and three for the test group) were intraperitoneally inoculated each with 1×10 6 parasitized red blood cells in a 0.2ml on day 0 (D0). Parasitaemia was then allowed to rise >5% when test mice were treated orally with AQ at a concentration equivalent to ED 99 . Parasite growth was then monitored to 2-7% when donor mice were selected for subsequent passage into the next naïve group of three mice. The parasites were then exposed to an increasing concentration of AQ in the subsequent passages based on parasite growth. Resistance level was evaluated at interval of four drug pressure passages by measurement of ED 50 and ED 90 in the standard 4DT. To determine the stability of the resistance, AQ selected parasite line was frozen at -80°C for at least one month followed by determination of ED 50 and ED 90 . This allowed us to calculate the 90% index of resistance (I 90 ) from the ratio of the ED 90 of the resistant line to that of sensitive parent line. Based on I 90 value, resistance levels were classified into four categories: i) I 90 = 1.0 (sensitive), ii) I 90 = 1.01-10.0 (slightly resistance), iii) I 90 =10.01-100, (moderate resistance), iv) I 90 ≥100 (high resistance) (Xiao et al., 2004) .
Generation of genetically homogenous parasite by dilution cloning During the selection of resistant lines, a high parasite density (1×10 6 ) is submitted to drug pressure, even though this parasite population may share common resistant markers, they however accumulate random mutations that may or not associate with resistance. We thus sought to generate a genetically homogeneous clone using a limiting dilution approach, as detailed by Janse et al., 2004. Briefly, a mouse with parasitaemia between 0.5 and 1% was selected as a donor mouse. 5µl of infected blood was collected from the tail snip of the mouse in 1µl of heparin and diluted in 1ml of 1×PBS. The number of infected erythrocytes per 1µl was estimated from 20µl of diluted blood. The cell suspension was then diluted further with 1×PBS to an estimated final concentration of 0.5 parasites/ 0.2ml PBS. 12 mice were then intravenously injected with the infected blood. Cloning was deemed successful when 3 to 6 mice become positive with a parasitaemia of between 0.3-0.5% at day 8 post infection. The fastest growing clone was selected for cross resistance and molecular studies.
Evaluation of cross resistance profiles
The sensitivity of the selected AQ-resistant parasites line against other antimalarial drugs, DEAQ, CQ, PMQ, PQ, ATM and LM, was also investigated by assessing the ED 50 and ED 90 in a the 4DT assay, as detailed previously, and the results compared to the ED 50 and ED 90 of sensitive parental line. To this purpose, four different drug concentrations were selected for each of the test drug and administered orally, except for DEAQ which was administered intraperitoneally. The 50% and 90% indices of resistance were calculated as previously discussed.
DNA extraction, PCR and sequencing of Pbmdr1, Pbcrt, Pbubp1 and PbKelch13
The identification of SNP in Pbmdr1, Pbcrt, Pbubp1 and PbKelch13 was carried out by sequencing, after DNA extraction and PCR amplification. Briefly, to extract parasite DNA, 500µl of blood from a mouse with 5-10% parasitaemia was diluted with 500µl of 1×PBS, the solution was spun for 1 min at 500×g. The supernatant was discarded and the pellet resuspended in 30ml volume of cold 4°C 1×erythrocytes lysis buffer for 30 minutes, followed by spinning at 500×g for 10 min. The parasite pellet was washed twice with 30ml 1×PBS with centrifugation at 500×g for 5 min at 4°C. Genomic DNA (gDNA) was extracted using a commercial QIAamp® Blood DNA extraction kit (Qiagen) following the manufacturer's instructions. As illustrated in Figure 1a -d, target fragments corresponding to specific regions of interest from P. falciparum ortholog genes, Pbcrt (PBANKA_1219500), Pbmdr1 (PBANKA_1237800), Pbubp1 (PBANKA_0208800) and PbKelch13 (PBANKA_ 1356700) were PCR amplified and sequenced using primers commercially synthesised at Inqaba Biotechnical Industries (Pty) Ltd, South Africa (Table 1a) . Briefly, 1µl of gDNA was used as the template in 25µl PCR reactions using DreamTaq (Thermo-Scientific™). Other reagents, MgCl 2 , dNTPs, primers and the cycling conditions, were optimized accordingly (Table 1b) . Products from PCR were first analysed in 1.5% agarose gel, purified using the GeneJet™ PCR purification kit (Thermo Scientific™) and then sequenced RNA extraction, cDNA synthesis and qRT-PCR assays The quantification of the mRNA transcripts of Pbmdr1, Pbvp2, Pbvcx1, and Pbnhe1 genes was carried out after cDNA synthesis from mRNA. Before extraction of RNA, all buffers and solutions for parasite preparation were first treated with 0.1% (v/v) of diethyl pyrocarbonate (DEPC). Total RNA was prepared from approximately 1×10 6 fresh parasites pellet. In preparation of parasite pellet, parasitized red blood cells were first washed in 1×PBS and then lysed in 5 volumes of ammonium chloride solution. The parasite pellet was washed twice in 10ml of 1×PBS and then resuspended in 200µl of 1×PBS. Total RNA was isolated using Quick-RNA™ MiniPrep (Zymo Research™) following the manufacturer's instructions. The first strand cDNA synthesis was performed in a final volume of 20µl using RevertAid First Strand cDNA synthesis kit and oligo-DT as primers. 5µg of total RNA, 1µl of oligo-DT and water were mixed with 4µl Reaction buffer (5×), 1µl RiboLock RNase Inhibitor (U/µl), 2µl of dNTPs (10mM) and 1µl of RevertAid M-MuLV RT (200U/µl). The reaction mix was incubated at 42°C for 60min, then at 70°C for 5min and finally chilled on ice. The cDNA was then used as template for qRT-PCR assays.
The mRNA transcript levels were evaluated using qRT-PCR in a final volume of 20µl using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific™). Oligonucleotide for Pbmdr1, Pbvp2, Pbvcx1 and Pbnhe1 were designed to run using similar cycling conditions relative to Pbβ-actin I, as the housekeeping gene (Table 2) . Briefly, 12µl of Maxima SYBR mix, 2.0µl (0.25µM) of forward and reverse primers each, 1µl cDNA and 3µl water were mixed. The reaction mix was run for pre-treatment at 50°C, for 2 min; initial denaturation at 95°C for 10 min; denaturation at 95°C for 15 secs; and annealing at 60°C for 60 secs for 45 cycles.
Statistical analysis
The means of expression levels of each gene from three independent experiments and from triplicate assays obtained from AQ resistant were compared to AQ sensitive using Student's t-test; p value was set at 0.05. The relative expression level results were normalized using Pbβ-actin I as the housekeeping using the formula 2 ΔΔ CT based on Livak & Schmittgen, 2001. The means for cross resistance profiles for each drug from at least four different drug concentrations was analysed using Student's t-test, with p value set at 0.05.
Ethical approval
This study was conducted at KEMRI. All animal work was carried out as per relevant national and international standards, as approved by KEMRI-Animal Use and Care Committee. Permission to carry out this study and ethical clearance were approved by KEMRI's Scientific Ethics Review Unit (No 3378).
Results and discussion
Amodiaquine drug pressure induces stable resistant phenotypes The current introduction of AQ as a fundamental component of ACT therapy (Gil, 2008) has spurred studies on understanding the mechanisms of AQ resistance. Using 2% Relapse Technique, AQ resistance has previously been selected in P. berghei and P. yoelii by submitting the parasite to 60 and 100mg/kg, respectively (Peters & Robinson, 1992); however, the stability, resistance indices and molecular mechanisms were not determined. Here we demonstrate that stable AQ resistant P. berghei ANKA can be achieved by submitting sensitive parasites to thirty-six continuous drug pressure passages (Dataset 1). To initiate selection of resistance, we first .05mg/kg/day, respectively. We adopted the serial technique, in which drug pressure is increased sequentially. 5.05mg/kg was selected as the starting drug pressure dose that was administered once percentage parasitaemia rose to 2-7%. At the onset, average parasitaemia reached 2-7% on day 3-4 post infection, after which dosage equivalent to ED 99 was administered. Figure 2 shows parasite responses to AQ at different passages during resistance selection process. The drug pressure dose was increased by a factor of ED 99 or based on parasite growth at different passage levels. Within the first 12 passages, administration of single 5mg/kg of AQ, after attaining >2% parasitaemia, cleared the parasite to below detectable levels by microscopy. Recurrence of >2% parasitaemia was only attained after 7-10 days on average; therefore, the drug pressure dose was not increased for the first 12 passages. From the 13 th passage, the parasite recrudescence after drug treatment reduced from 7 days to 3-4 days. We henceforward increased the drug pressure dose by a factor of 1.5 of ED 99 (equivalent to 2.5mg/kg) every two passages up to the 20 th passage when the dosage was further increased by a factor of 2 of ED 99 (equivalent to 5mg/kg) every two passages. By the 36 th passage, the drug pressure dosage had risen to 50mg/kg, which was 50 and 10 times higher than the ED 50 and ED 99 respectively, we thus expected a higher ED 50 and ED 90 . Surprisingly the I 50 and I 90 was only 12 and 4 folds respectively (Table 3a) . The resistant line remained stable after freezing at -80°C for at least one month, with ED 50 and ED 90 of 5.86 mg/kg and 18.22mg/kg respectively. The effective doses were equivalent to I 50 and I 90 of 6-and 4-fold respectively, meaning that stable AQ resistant P. berghei line was successfully selected and the resistance mechanisms were probably encoded in the cell genome.
Amodiaquine resistance associated with cross resistance to CQ, LM, PMQ, PQ and ATM Selection of stable AQ resistant line allowed us to study whether AQ resistance is associated with reducing efficacy of other antimalarial drugs (Dataset 2). Using dilution cloned parasite, we determined the ED 90 of PQ, LM, PMQ and ATM against both AQ sensitive and AQ resistant parasite. To our surprise, AQ resistance was associated with moderate and slight resistance to ATM (I 90 = 10.2) and PMQ (I 90 = 5.8), respectively. Interestingly, AQ resistant line was less resistant to PQ (I 90 = 2.2-fold) than LM (I 90 = 3.5-fold), despite PQ and AQ belonging to the same chemical class of 4-aminoquinoline and LM belonging to different chemical class of aryl-alcohols (Table 3b ). This means that AQ resistant phenotype is accompanied by mechanisms that confer resistance to ATM, LM, PQ, PMQ and CQ. The crossresistance profile is not surprising for drugs such as CQ and PQ, since they are quinoline based compounds molecules, and chemically related to AQ, thus may share some resistance mechanisms. Indeed, selection of CQ resistance in P. berghei has previously been shown to confer cross-resistance to AQ, mefloquine and PMQ, two quinoline based drugs (Platel et al., 1998) . Similarly, we expect PMQ (8-amino quinoline) and LM (an aryl-alcohol) to share certain mechanisms with 4-amino quinoline based on similarity of modes of action. However, the high cross resistance levels for ATM (I 90 = 10fold) is entirely surprisingly. ATM 
Evaluation of point mutation in Pbcrt, Pbmdr1, Pbubp1 and PbKelch13 (Dataset 3)
To investigate the possible mechanisms of AQ resistance, we evaluated polymorphisms in two P. berghei orthologs genes, Pbcrt and Pbmdr1, known to be associated with quinoline resistance in P. falciparum, and our study focused on regions of the genes that contained the reported point mutations in P. falciparum (Figure 1a and b) . To date, several studies have demonstrated the association between resistance or decrease susceptibility to 4-amino-quinoline resistance and mutation in crt gene, changes in expression profiles and/or copy number variation in mdr1 gene ( . We hypothesised that PbKelch13 may possess SNPs, and thus mediate this cross resistance. Our data showed no mutation in PbKelch13 domain of AQ resistant line, thus AQ and ATM resistance observed in vivo is not associated with SNPs in Kelch13 domain. We focused our study on Kelch13, however other genes such as TCTP, SERCA and PI3P reported to associate with mechanisms of artemisinins action or resistance in P. falciparum (Eckstein-Ludwig et al., 2003) may also be linked with our selected AQ resistant line. As the index of resistance to ATM (I 90 = 10.2) was double that of AQ (I 90 = 4.2) indicate that AQ and ATM could share some resistance mechanisms in P. berghei. Thus, these AQ resistant lines could be used to define these common mechanisms and some of them may be TCTP, SERCA and PI3P or other unknown genes.
The V739F and V770F mutations in ubp1 C-terminal conserved region are associated with artesunate resistance in P. chabaudi (Hunt et al., 2010) . Similarly, Tyr835Ly and Ser836Gln mutations were mapped in both LM and PQ resistant P. berghei (unpublished data; Kiboi, Irungu, Orwa, Kamau, Ochola-Oyier, Ng'ang'a and Nzila). In our current study, the analysis of the sequence fragments flanking 739, 770, 834 and 835 position of the PbUBP1 protein revealed no amino acid changes in the selected AQ resistant line. Studies in P. falciparum in vitro also found no association between artemisinin resistance and mutation in ubp1 (Chavchich et al., 2010); however analysis of field P. falciparum isolates from Western Kenya associated Pfubp1 Glu1528Asp mutation with tolerance to artemisinin (Henriques et al., 2014). We thus envisage complex mechanisms controlling loss of ATM efficacy in the AQ resistant phenotype. Examining the whole genome and transcriptome profile may expose these complex networks.
High mRNA transcripts of Pbmdr1, Pbnhe1, Pbvp2 and Pbcvx1 associated with AQ resistance To further probe other possible mechanisms of AQ resistance, we hypothesised that major transporters or ion exchangers, Pbmdr1, Pbnhe1, Pbvp2 and Pbcvx1 could mediate AQ resistance via altered mRNA transcript levels (Dataset 3). The results show that the mRNA transcript of Pbmdr1 and Pbvp2 were elevated 3.0fold (p<0.0001) and 2.3fold (p<0.0001), respectively (Figure 3) . In relation to Pbnhe1 and Pbcvx1, AQ resistant parasites have a significantly high amount of Pbnhe1 mRNA transcripts of 2.6fold compared to sensitive line (p<0.0001), and similar results were observed on Pbcvx1, 1.7fold (p<0.001) (Figure 3) . Therefore, elevated mdr1, vp2, cvx1 and nhe1 transcript level is associated with AQ resistance. First, overexpression of mdr1 is a common marker for P. falciparum resistant to MQ, AQ, CQ and ATM (Borges et al., 2011; Gonzales et al., 2008) . In addition, the mdr1 regulates transcription of other drug resistance genes (Gonzales et al., 2008; Jiang et al., 2008) . For instance, augmenting CQ resistance in parasites harbouring Pfcrt K76T mutation (Fidock et al., 2000) . We thus argue that mdr1 overexpression may play a direct role in mediating AQ resistance.
Two genes, vp2 and cvx1, are H + channel molecules that play two roles in CQ resistance: regulation of pH balance in the parasite's food vacuole and a compensatory role (adaptive changes in response to mutation in drug resistance genes) in a mutated Pfcrt protein (Jiang et al., 2008) . In a recent report, PQ resistance was associated with high vp2 and cvx1 expression in P. berghei, though there was no mutation in Pbcrt gene (Kiboi et al., 2014) . The AQ resistant line carried His95Pro mutation in PbCRT protein, thus elevation of vp2 and cvx1 may compensate for this mutation, as it has been reported with the Lys76Thr crt mutation in P. falciparum. To date, the proffered mode of action for CQ, AQ and PQ is the inhibition of heme polymerization within the food vacuole (O'Neill et al., 2011). Based on this mode of action, some resistance mechanisms associated with AQ may involve proteins within the food vacuole. We thus argue that high vp2 and cvx1 expression may play a role in + antiporter (vcx1), as measured from cDNA amount derived from 5µg of total RNA isolated from amodiaquine resistance (AQR), relative to the wild type amodiaquine sensitive (AQS) clones. The differential expression from a mean of three independent experiments were significantly different for mdr1 (p<0.0001), nhe1 (p<0.0001), vp2 (p<0.0001) and cvx1 (p<0.001), after Student's t-test analysis with p-value set at 0.05.
regulating pH balance in AQ resistance. Lastly, we report a 2.6-fold increase in nhe1 mRNA transcript in AQ resistance in P. berghei ANKA. A report in P. falciparum has shown that quinine resistance can be associated with increased expression of nhe1 in the presence of mutations in Pfcrt and Pfmdr1 (Nkrumah et al., 2009 ). Since the role of the nhe1 is to regulate Na + /H + exchange, this ion exchange may also contribute in AQ resistance phenotype.
In conclusion, we provide important evidence in relation to AQ resistance in P. berghei ANKA. First, emergence of AQ resistance is associated with cross resistance to ATM, PMQ, LM, PQ and CQ, thus this is a "multi-drug" resistant line. Second, novel His95Pro mutation in PbCRT is associated with AQ resistance and may well mediate the cross-resistance profiles. Third, one route for acquiring AQ resistance is via increased transcription of mdr1, nhe1, vp2 and cvx1 genes. These genes are associated with increasing resistance levels and conferring physiological advantage to drug resistance genes that may possess biologically deleterious mutations (Gonzales et al., 2008) . The elevated expression of these genes is consistent with P. falciparum resistance to CQ, LM and ATM (Gonzales et al., 2008; Jiang et al., 2008; Mwai et al., 2012) , suggesting that some mechanisms between P. falciparum and P. berghei are similar. Finally, AQ resistance and its associated cross resistance profiles are independent of SNPs in ubp1 and Kelch13 genes. Studies are underway to explore whole genome to reveal other possible SNPs and copy number variants associated with AQ resistance.
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in vivo Plasmodium parasites. This represents an essential first-step in the elucidation of genetic determinants berghei underlying the resistance phenotype. As the authors note, further characterization of the lines (whole genome sequencing/RNA-seq/genetic backcross), along with validation studies will be required to further support this association based initial characterization.
From the Methods section, it is unclear if the ANKA line was cloned prior to selection P. berghei experiments. This would limit the impact that initial sub-populations contribute to the identified pre-selection/post-selection genetic variances. If the line wasn't cloned prior to the selection this may partially explain the multiple genetic differences identified (Pbcrt SNP along with expression variance in four distinct transporters).
It is unclear from the Methods section if independent PCR reactions/sequencing of both strands were performed on the target loci indicated in Figure 1 , to address polymerase/sequencing errors.
The depiction of the drug selection procedure in Figure 2 is confusing as the parasites were subjected to an increasing drug concentration selection (initial oral treatment of the AQ ED99 concentration and "increasing concentrations…based on parasite growth"), not two groups (either 2.5 or 5mg/kg/day) as indicated. The figure should be revised to indicate the selection concentration used for each passage and day 4 parasitemia. Also unclear from the methods/figure is the robustness of the selection for each passage. As three mice were inoculated per passage, was there any variance in the positivity/parasitemia of the mice upon selection pressure? If these lines/sub-passages are preserved they may represent an exciting tool to dissect the evolution of AQ resistance (in a similar manner that Hunt discerned drug resistance in ). et al.
P. chabaudi
The authors utilize a single parasite freeze/thaw to assess stability of the drug resistance phenotype. It is suggested that serial passage in naïve, non-drug treated mice is a more stringent evaluation of the resistance stability. Another method would be the passage of the line through the mosquito stage (which could also be run in parallel with genetic back-crossing of the line). The 4.
5.
evaluation of the resistance stability. Another method would be the passage of the line through the mosquito stage (which could also be run in parallel with genetic back-crossing of the line). The lower IC50 and IC90 values after the freeze/thaw suggest some instability in the drug-resistance phenotype.
As the drug dose response is sigmodal a non-linear regression analysis is usually preferred. Although a linear regression analysis would typically have good estimation of the IC50 value, due to the linear nature of the slope, there is disparity in calculation of the IC90 value using a linear regression analysis. PbKelch13 genes.
Is
2. We amplified independent amplicons and sequenced in both forward and reverse direction. To have repeated the experiment by PCR amplifying and sequencing the whole coding region for both and . To minimise the possible polymerase errors, we used a proof-reading Pbcrt Pbmdr1 genes polymerase (Phusion Flash High Fidelity PCR Master Mix, Thermo Fisher Scientific). We have added these statements in the methodology and results section 3.We have used percentage parasitaemia recorded during the drug selection process to revise 3.We have used percentage parasitaemia recorded during the drug selection process to revise Figure 2 . We have revised the Figure 2 to show the percentage parasitaemia during selection process relative to the increasing drug pressure dosage. In response to the second question on the parasitaemia variance during the selection process. We recorded variances in the parasitaemia between the three mice used for selecting AQ resistance at each of the drug pressure passage. Parasite lines for each mouse and at each drug pressure passage were cryopreserved. We agree with the reviewer that one robust way of dissecting the mechanisms of AQ resistance is to use the Linkage Group Selection (Culleton et al. 2005 ; Hunt et al. 2007; 2010) followed by whole genome and transcriptome sequencing. We hope to use these approaches in our current studies.
4. We concur with the reviewers that performing drug-free passage is a more stringent approach for ascertaining the stability of the AQ resistant. We therefore evaluated and confirmed the stability of the AQ resistant parasite by culturing the resistant parasite for a total of ten passages in the absence of the AQ. We then determined the ED and ED using the standard 4DT test. Figure 3 illustrates this data on the stability of the mutant parasites. Table 3a also contains the new computed ED and indices of resistance.
5.We consistently used the linear regression analysis in estimation of the ED50 and ED90. Since, the linear regression would provide a good estimate, we presume our results on the ED50 and ED90 would correlate well across the different assays we conducted.
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To provide a comprehensive assessment of the genetic basis of resistance, the authors should perform whole-genome sequence analysis of the mutant compared to the parental line. If that is not feasible, the authors should at the very least complete their sequencing of the entire coding sequence for both PbCRT and . For , full-length sequences can be obtained from reverse-transcribed cDNA (they Pbmdr1 PbCRT already report making RNA for some of their qRT-PCR studies).
Other points:
Introduction: It is not entirely correct that selected resistant parasites in are generally P. falciparum not stable. This argument should be removed. Concluding that the lines have a stable resistant phenotype after being stored at -80°C for one month is an overstretch. Stability usually means that the phenotype persists for one month or more of continuous propagation without drug pressure. Especially as the ED and I values post-thawing are ~1/2 that of the pre-freezing line on passage #36 (see Table 3A ). The authors should either test for true stability in the absence of drug, or remove this as a central finding of their study. Table 3B -the authors cannot base any changes in mutant parasite susceptibility to primaquine or lumefantrine based on a comparison with earlier published data for those drugs with the sensitive parental line. If the parent was not tested here in parallel with the mutant for these drugs, then those data should be removed, or at the very least they should attenuate their statements and list the caveat that data for the parental line were from separate studies and thus shifts in susceptibility have not been directly demonstrated. Also for Table 3 , the authors need to list how the number of independent experiments and mouse group sizes.
On page 10 the authors state that overepression is a common marker of resistance to Pfmdr1 chloroquine. Results presented in Sidhu 2007 J Infect Dis showed no change in chloroquine et al IC in isogenic lines with different copy numbers and that work should be cited. Pfmdr1 Figure 2 is hard to understand as it seems to indicate that selection was only performed at two fixed concentrations, whereas resistance was obtained using a ramping procedure. The authors should clarify what is being shown. We concur that performing whole genome sequencing of the resistant line may comprehensively dissect AQ resistance markers. This objective is in our current study plan; however, we have sequenced full-length of and genes from cDNA. We have edited the methods the Pbcrt Pbmdr1 section to highlight the sequencing approach and included this data in the results section. We have also revised the Figure 1 to portray the sequenced region of the other two genes; Pbubp1 and Pbkelch13. We have included the new sequence data in dataset 3.
Response to other comments 1. We have removed the statement on "that selected resistant parasites in are P. falciparum generally not stable." 2. We have edited the Figure 1 to portray the regions of the genes that were adequately sequenced 3. We tested the stability of the AQ resistant parasite by culturing the resistant parasite for a total of ten passages in the absence of the AQ. We then determined the 50% and 90% effective dosages (ED and ED ) using the standard 4DT test. In the MATERIALS AND METHODS section, we have included a statement on the stability assays, under the subsection "Submission of the parasite to AQ pressure and Resistance Level Test. In the RESULTS AND DISCUSSION section, we have included the ED and ED values in Table 3a to illustrate the stability of the AQ-resistant parasites. We have included Figure 3 to show the drug response profile of the AQR, drug-free parasite and drug sensitive parent line. This data is under subsection on "Amodiaquine drug pressure induces stable-resistant phenotypes" We have included a new figure (Figure 3 ) in our revised version.
4. We have retested the ED for primaquine and lumefantrine against the sensitive parent parasite. We have included the new data on ED in Table 3b and the raw data in dataset 2. We used at least four different drug concentrations and at least four Swiss mice per drug concentration. We have clarified this statement in Table 3a. 5. We have included the statement on the lack of association between CQ resistance and the order appears to be rather random.
I believe that selecting lines of malaria parasites for drug resistance to understand its genetic basis is essential to provide effective therapies for the treatment of this disease. Thus the work presented here is of interest to the scientific community, but only if the authors address the aforementioned issues.
I also understand that the authors are in the process of sequencing the whole genome (and I presume transcriptome) of their AQ resistant line and it will be interesting to see what mutations may have arisen. If the line is indeed phenotypically stable, the authors should consider crossing it with a genetically distinct susceptible strain and then apply Linkage Group Selection (Culleton , 2005) to identify mutations et al underlying the phenotype. I could provide more details about how to proceed, should the authors decide to do so. We thank the referee for insightful comments.
To address the experimental concern raised, we are currently carrying out further experimentation on stability test. We choose to pass the parasite line through mice for at least five-ten drug free passages. We will then determine the resistance level after the drug free passages.
We recognize that passing the resistant line through mosquitoes as one of the ways of verifying stability of the phenotype. Since this is an ongoing project, we hope to use this approach as well before sequencing the genome and the transcriptome of the resistant line.
To address the second major concern, we have requested a native English speaker to assist in rewriting and improving the manuscript to the required publication standards.
